Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Next Previous
Trial Profile

A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simufilam (Primary)
  • Indications Alzheimer's disease
  • Focus First in man; Pharmacokinetics
  • Sponsors Cassava Sciences; Filana Therapeutics; Pain Therapeutics

Most Recent Events

  • 10 Mar 2026 According to Cassava Sciences media release, Cassava Sciences is now called Filana Therapeutics.
  • 14 Dec 2017 According to a Pain Therapeutics media release, full results of this study were presented at the 10th Annual International Conference on Clinical Trials on Alzheimers Disease (CTAD) 2017.
  • 24 Oct 2017 According to a Pain Therapeutics media release, this trial was supported with research grant award from the National Institute on Aging, part of the National Institutes of Health.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top